You have 9 free searches left this month | to do more
Showing 1 - 25 of
>10,000 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
C
A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell Transfusions
Recruiting
  • Myelodysplastic Syndromes
  • Beijing, China
  • +23 more
2022-02-03
Feb 3, 2022
C
An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion
Recruiting
  • Myelodysplastic Syndromes
  • Chiba, Japan
  • +18 more
2022-01-08
Jan 8, 2022
C
A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes - 2020
Completed
Has Results
  • Myelodysplastic Syndromes
  • Stanford, California
  • +73 more
2021-11-19
Nov 19, 2021
C
A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve
Recruiting
  • Myelodysplastic Syndromes
  • Birmingham, Alabama
  • +239 more
2022-03-15
Mar 15, 2022
S
A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS - 2022
Completed
  • Anemia in Myelodysplastic Syndromes
  • Plantation, Florida
  • +2 more
2022-04-04
Apr 4, 2022
N
A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).
Active, not recruiting
  • Myelodysplastic Syndromes
  • Duarte, California
  • +46 more
2022-02-01
Feb 1, 2022
N
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
Active, not recruiting
  • Myelodysplastic Syndromes
  • Leukemia, Myelomonocytic, Chronic
  • Yuma, Arizona
  • +148 more
2022-03-07
Mar 7, 2022
F
A Study of FF-10501-01 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome
Withdrawn
  • Myelodysplastic Syndrome (MDS)
  • (no location specified)
2021-07-20
Jul 20, 2021
G
Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)
Active, not recruiting
  • Myelodysplastic Syndromes
  • Birmingham, Alabama
  • +153 more
2022-02-03
Feb 3, 2022
U
Allogeneic HSCT in MDS Patients Based on Risk According to R-IPSS
Recruiting
  • MDS and Allogeneic Stem Cell Transplantation
  • MDS and AlloHSCT
  • Perugia, PG, Italy
    University of Perugia
2021-03-11
Mar 11, 2021
S
A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS)
Not yet recruiting
  • Myelodysplastic Syndrome
  • Guangzhou, Guangdong, China
  • +1 more
2021-06-04
Jun 4, 2021
U
Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS Patients
Recruiting
  • MDS
  • CMML
  • Florence, Italy
    AOU Careggi- University of Florence
2021-03-16
Mar 16, 2021
U
Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients
Not yet recruiting
  • Anemia
  • Myelodysplastic Syndromes
  • Canakinumab Injection
  • Berlin, Germany
  • +5 more
2022-02-14
Feb 14, 2022
O
Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA
Active, not recruiting
  • Myelodysplastic Syndrome
  • +3 more
  • La Jolla, California
  • +157 more
2021-06-11
Jun 11, 2021
S
A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS - 2021
Completed
  • Myelodysplastic Syndromes (MDS)
  • Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine
  • Chicago, Illinois
  • +11 more
2022-04-04
Apr 4, 2022
P
Hetrombopag for Low/Intermediate-1 Risk MDS With Thrombocytopenia
Not yet recruiting
  • MDS
  • Beijing, China
    Peking Union Medical College Hospital
2021-09-18
Sep 18, 2021
A
Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS
Recruiting
  • Myelodysplastic Syndromes
  • ASTX727 LD
  • ASTX727 SD
  • Anniston, Alabama
  • +25 more
2022-01-14
Jan 14, 2022
B
A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Not yet recruiting
  • Myelodysplastic Syndrome (MDS)
  • BLEX 404 Oral Liquid
  • (no location specified)
2021-09-07
Sep 7, 2021
N
Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients - 2008
Completed
Has Results
  • Myelodysplastic Syndromes
  • Iron Overload
  • Stanford, California
  • +2 more
2021-06-01
Jun 1, 2021
C
Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome
Recruiting
  • Acute Myeloid Leukemia, in Relapse
  • Myelodysplastic Syndromes
  • Scottsdale, Arizona
  • +8 more
2021-05-17
May 17, 2021
G
VALIDATION OF A PREDICTIVE MODEL OF RESPONSE TO ROMIPLOSTIM IN PATIENTS WITH IPSS LOW OR INTERMEDIATE-1 RISK MDS AND THROMBOCYTOPENIA - 2021
Completed
  • Myelodysplastic Syndromes
  • N-Plate / romiplostim
  • Annecy, France
  • +35 more
2021-09-07
Sep 7, 2021
G
Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Recruiting
  • Myelodysplastic Syndromes
  • Birmingham, Alabama
  • +137 more
2022-04-07
Apr 7, 2022
C
The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)
Active, not recruiting
Has Results
  • Myelodysplastic Syndrome
  • Oral Azacitidine
  • +2 more
  • Berkeley, California
  • +195 more
2021-12-20
Dec 20, 2021
T
CVA Regimen Bridging to HSCT for R/R AL
Recruiting
  • Acute Leukemia, in Relapse
  • Acute Leukemia Refractory
  • CVA regimen bridging to HSCT
  • Suzhou, Jiangsu, China
    The First Affliated Hospital of Soochow University
2022-01-04
Jan 4, 2022
N
A Phase Ib/IIa Study Evaluating the Safety and Tolerability of Vitamin C in Patients With Intermediate or High Risk Myelodysplastic Syndrome With TET2 Mutations
Recruiting
  • Myelodysplastic Syndromes
  • 50 gm CIVI/24 hours x 5 days every 4 week
  • Miami, Florida
  • +1 more
2021-08-27
Aug 27, 2021